Patents by Inventor Eugene C. Yi
Eugene C. Yi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230159650Abstract: The present invention relates to a composition for preventing or treating diseases caused by overexpression of chemokine CX3CL1 (fractalkine) comprising a death receptor 5 (DR5) inhibitor as an active ingredient, a method for preventing or treating diseases caused by overexpression of chemokine CX3CL1 comprising administering a DR5 expression or activity inhibitor to a patient in need of prevention or treatment of diseases caused by overexpression of chemokine CX3CL1 in a therapeutically effective amount, and a use for prevention or treatment of diseases caused by overexpression of chemokine CX3CL1 of a DR5 expression or activity inhibitor.Type: ApplicationFiled: August 14, 2018Publication date: May 25, 2023Inventors: Doo Hyun CHUNG, Eugene C. YI, Dongjin JEONG, Min Jueng KANG, Donghyun KIM
-
Publication number: 20210221847Abstract: A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.Type: ApplicationFiled: July 2, 2019Publication date: July 22, 2021Inventors: Yeong Wook SONG, Joo Youn LEE, Eugene C. YI, Min Jueng KANG
-
Patent number: 10150961Abstract: The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level.Type: GrantFiled: July 19, 2013Date of Patent: December 11, 2018Assignees: Seoul National University R&DB Foundation, Kangwon National University Industry Cooperation FoundationInventors: Eugene C. Yi, Min Jueng Kang, Kristine M. Kim, Eunhee G. Kim
-
Publication number: 20180258172Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.Type: ApplicationFiled: May 24, 2018Publication date: September 13, 2018Inventors: Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
-
Patent number: 10005837Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.Type: GrantFiled: January 21, 2015Date of Patent: June 26, 2018Assignee: Zymogenetics, Inc.Inventors: Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
-
Patent number: 9708390Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.Type: GrantFiled: July 11, 2016Date of Patent: July 18, 2017Assignee: ZYMOGENETICS, INC.Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
-
Publication number: 20160311909Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.Type: ApplicationFiled: July 11, 2016Publication date: October 27, 2016Inventors: Pallavur V. SIVAKUMAR, Debra G. Gilberson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
-
Publication number: 20160274106Abstract: The present invention relates to a composition and kit for rheumatoid arthritis diagnosis or activity evaluation, the composition and kit each including an agent for measuring the concentration of at least one protein selected from a group consisting of soluble CD14 (sCD14), a-1-acid glycoprotein 1 (AGP1), and a-1-acid glycoprotein 2 (AGP2). Further, the present invention relates to a use of the composition for diagnosing rheumatoid arthritis or evaluating activity.Type: ApplicationFiled: June 20, 2014Publication date: September 22, 2016Applicant: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Wan-Uk KIM, Daehee HWANG, Eugene C. YI, Min Jueng KANG, Yune Jung PARK, Sung youg YOU
-
Patent number: 9441034Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.Type: GrantFiled: March 27, 2009Date of Patent: September 13, 2016Assignee: ZYMOGENETICS, INC.Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
-
Publication number: 20150175702Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.Type: ApplicationFiled: January 21, 2015Publication date: June 25, 2015Inventors: Cameron S. BRANDT, Jacob J. Kennedy, Wenfeng Xu, Eugene C. YI, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
-
Patent number: 8969518Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.Type: GrantFiled: November 10, 2010Date of Patent: March 3, 2015Assignee: Zymogenetics, Inc.Inventors: Cameron S. Brandt, Jacob J. Kennedy, Wenfeng Xu, Eugene C. Yi, Brian A. Fox, Zeren Gao, Pallavur V. Sivakumar
-
Publication number: 20140162890Abstract: The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level.Type: ApplicationFiled: July 19, 2013Publication date: June 12, 2014Inventors: Eugene C. Yi, Min Jueng Kang, Kristine M. Kim, Eunhee G. Kim
-
Patent number: 8361470Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.Type: GrantFiled: May 17, 2012Date of Patent: January 29, 2013Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120225065Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: May 17, 2012Publication date: September 6, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Patent number: 8241629Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: December 17, 2010Date of Patent: August 14, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 8226948Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: January 11, 2012Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20120177655Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ZYMOGENETICS, INC.Inventors: Stephen R. JASPERS, Mark W. RIXON, Stacey R. DILLON, Frederick J. RAMSDELL, Cecile M. KREJSA, Eugene C. YI
-
Patent number: 8124089Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: GrantFiled: June 11, 2009Date of Patent: February 28, 2012Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20110177074Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.Type: ApplicationFiled: March 27, 2009Publication date: July 21, 2011Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell
-
Publication number: 20110130548Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: December 17, 2010Publication date: June 2, 2011Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi